Yesterday, Jan. 5, 2016, 42 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $358.13 to $953,600,000.00.

Highlighted Stocks Traded by Insiders:

Tallgrass Energy Partners (TEP) - FREE Research Report

Tallgrass Operations, LLC, who is 10% Owner at Tallgrass Energy Partners, sold 20.0 million shares at $47.68 on Jan. 5, 2016. Following this transaction, the 10% Owner owned 6.4 million shares meaning that the stake was reduced by 75.89% with the 20.0 million-share transaction.

The shares most recently traded at $39.77, down $7.91, or 19.89% since the insider transaction. Historical insider transactions for Tallgrass Energy Partners go as follows:

  • 4-Week # shares bought: 10,000
  • 12-Week # shares bought: 10,000
  • 24-Week # shares bought: 21,000

The average volume for Tallgrass Energy Partners has been 215,200 shares per day over the past 30 days. Tallgrass Energy Partners has a market cap of $2.5 billion and is part of the basic materials sector and energy industry. Shares are up 0.32% year-to-date as of the close of trading on Tuesday.

Tallgrass Energy Partners, LP acquires, owns, develops, and operates various midstream energy assets in North America. The company operates through three segments: Natural Gas Transportation & Logistics; Crude Oil Transportation & Logistics; and Processing & Logistics. The stock currently has a dividend yield of 6.19%. The company has a P/E ratio of 20.9. Currently, there are 9 analysts who rate Tallgrass Energy Partners a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on TEP - FREE

TheStreet Quant Ratings rates Tallgrass Energy Partners as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the stock has had a decline in price during the past year. Get the full Tallgrass Energy Partners Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cirrus Logic (CRUS) - FREE Research Report

Sherman William D, who is Director at Cirrus Logic, sold 339 shares at $29.35 on Jan. 5, 2016. Following this transaction, the Director owned 11,144 shares meaning that the stake was reduced by 2.95% with the 339-share transaction.

The shares most recently traded at $27.82, down $1.53, or 5.5% since the insider transaction. Historical insider transactions for Cirrus Logic go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 5,667
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 9,296
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 21,463

The average volume for Cirrus Logic has been 1.9 million shares per day over the past 30 days. Cirrus Logic has a market cap of $1.9 billion and is part of the technology sector and electronics industry. Shares are down 6.64% year-to-date as of the close of trading on Tuesday.

Cirrus Logic, Inc., a fabless semiconductor company, develops analog and mixed-signal integrated circuits for a range of consumer and industrial markets. The company has a P/E ratio of 8.3. Currently, there are 5 analysts who rate Cirrus Logic a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRUS - FREE

TheStreet Quant Ratings rates Cirrus Logic as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, attractive valuation levels and compelling growth in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Cirrus Logic Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Anacor Pharmaceuticals (ANAC) - FREE Research Report

Berns Paul L, who is President and CEO at Anacor Pharmaceuticals, sold 2,533 shares at $112.35 on Jan. 5, 2016. Following this transaction, the President and CEO owned 252,227 shares meaning that the stake was reduced by 0.99% with the 2,533-share transaction.

Ippolito Vincent P, who is EVP & Chief Commercial Officer at Anacor Pharmaceuticals, sold 855 shares at $112.28 on Jan. 5, 2016. Following this transaction, the EVP & Chief Commercial Officer owned 70,985 shares meaning that the stake was reduced by 1.19% with the 855-share transaction.

Sullivan Ryan T, who is Sr. VP and General Counsel at Anacor Pharmaceuticals, sold 733 shares at $111.78 on Jan. 5, 2016. Following this transaction, the Sr. VP and General Counsel owned 27,007 shares meaning that the stake was reduced by 2.64% with the 733-share transaction.

The shares most recently traded at $110.91, down $0.87, or 0.79% since the insider transaction. Historical insider transactions for Anacor Pharmaceuticals go as follows:

  • 4-Week # shares sold: 40,000
  • 12-Week # shares sold: 40,000
  • 24-Week # shares sold: 40,000

The average volume for Anacor Pharmaceuticals has been 743,700 shares per day over the past 30 days. Anacor Pharmaceuticals has a market cap of $5.0 billion and is part of the health care sector and drugs industry. Shares are up 1.15% year-to-date as of the close of trading on Tuesday.

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It markets KERYDIN (tavaborole) topical solution for the treatment of onychomycosis of the toenails. Currently, there are 3 analysts who rate Anacor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANAC - FREE

TheStreet Quant Ratings rates Anacor Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and weak operating cash flow. Get the full Anacor Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.